| Literature DB >> 15635635 |
Robert G Boyle1, John Humphries, Tim Mitchell, Graham A Showell, Robert Apaya, Hiroaki Iijima, Hiroshi Shimada, Tomonori Arai, Hiroaki Ueno, Yoshihiro Usui, Toshiro Sakaki, Etsuko Wada, Keiji Wada.
Abstract
Extensive SAR studies on the unselective BRS3 agonist, [H-D-Phe6,beta-Ala11,Phe13,Nle14]-bombesin-(6-14)-nonapeptide amide, have highlighted structural features important for BRS3 activity and have provided guidance as to the design of selective agonists. A radically modified heptapeptide agonist, maintaining only the Trp-Ala moiety of the parent [H-D-Phe6,betaAla11,Phe13,Nle14]-peptide amide, and with a very different carboxyl terminal region, has been produced which was potent at BRS3 and essentially had no NMB or GRP receptor activity. Its structure is Ac-Phe-Trp-Ala-His(tauBzl)-Nip-Gly-Arg-NH2. Copyright (c) 2004 European Peptide Society and John Wiley & Sons, Ltd.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15635635 DOI: 10.1002/psc.599
Source DB: PubMed Journal: J Pept Sci ISSN: 1075-2617 Impact factor: 1.905